Ketamine for Methamphetamine Use Disorder
At a glance
Conditions
NCT06496750
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Addiction Institute of Mount Sinai
New York, New Yorkno site contact published
Alameda Health System
San Leandro, Californiano site contact published
Interdisciplinary Substance Use and Brain Injury Facility
Albuquerque, New Mexicono site contact published
Prisma Health
Greenville, South Carolinano site contact published
UT Southwestern Medical Center
Dallas, Texasno site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Madhukar Trivedi, MD · PRINCIPAL_INVESTIGATOR · Professor (Tenured)
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Treatment Response2 weeks
Defined as having at least three methamphetamine-negative urine samples out of four samples obtained during Weeks 3 and 4.